EGFR and cholangiocarcinoma: revealed that the interaction between MUC1 and EGFR activates the EGFR/PI3K/Akt pathway, leading to the accumulation of Foxp3+ Tregs, aiding tumor immune evasion and thus promoting cholangiocarcinoma development and metastasis (113).